Fig. 1. Comparative antiproliferative impact of ribociclib plus letrozole and multi-agent chemotherapy on luminal B Breast Cancer, as measured by Ki67 expression.

a Individual paired Ki67 expression at baseline and surgery after treatment with ribociclib and letrozole and multi-agent chemotherapy. Colored lines represent individual patient data. b Mean percentage rate of response as determined by complete cell-cycle arrest (CCCA, Ki67 < 2.7%), at week 2 and surgery by treatment arms. c Expression of Ki67 across the three timepoints (Baseline, day 14, surgery) in ribociclib and chemotherapy arms. p-value was obtained after performing ANOVA test. d Individual paired Ki67 expression at baseline, day 14, and surgery. Colored lines represent individual patient data. e Change in Ki67 expression between week 2 and surgery by interval between ribociclib or paclitaxel discontinuation and surgery. Each point represents a patient.